View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Joint Bone Spine 2022; 89:105416 doi: 10.1016/j.jbspin.2022.105416
In this multi-centric, real-world study, persistence with secukinumab and TNFi were not statistically different for matched populations. The primary outcome of this analysis was drug persistence, calculated as the difference in months between initiation and discontinuation.
Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00498-x
Post hoc analysis from the FINCH 1 study highlights filgotinib as a potential beneficial treatment option for patients with RA who have had inadequate response to MTX and have high risk of disease progression and poor prognosis.
Joint Bone Spine. 2022 doi.org/10.1016/j.jbspin.2022.105358
This study from Ruyssen-Witrand et al, highlights that the probability of being in drug free remission at 5-year in patients with recent onset of axSpA is low. The study was performed to investigate the possible association between demographic, clinical, biological and imaging characteristics and drug-free remission at 5 years.
Arthritis Rheumatol. 2022 doi: 10.1002/art.42149
Bruckmann et al carried out this observational, proof of concept study to analyse the effect anti-TNF-therapy (TNFi) on inflammatory, structural, and osteoblastic activity lesions in radiographic axial spondyloarthritis (r-axSpA).
